RCE Insider Trading

Insider Ownership Percentage: 33.63%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$334,562.00

Recce Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Recce Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Recce Pharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/12/2020 01:00 AM ET

This chart shows the closing price history over time for RCE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Recce Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2023Michele DiliziaInsiderSell836,405A$0.40A$334,562.00
6/22/2023James GrahamInsiderBuy500,000A$0.59A$295,000.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Recce Pharmaceuticals (ASX:RCE)

6.53% of Recce Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Recce Pharmaceuticals logo
Recce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, the company engages in R327 Intravenous which provides serious/life-threatening bacterial infections, including sepsis which is in the phase 1 trial; urinary tract infections, including urosepsis; rapid infusions sepsis in the phase 2 trial; and R327 Topical offers wound infections, including infected burns; and diabetic foot ulcer infections in Phase 2 trails. Further, the company operates various pre-clinical programs, such as Mycobacterium abscessus which is in phase 1 clinical trial; bacterial sinusitis; and additional TBA. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Read More on Recce Pharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

630,087 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Who are the company insiders with the largest holdings of Recce Pharmaceuticals?

Recce Pharmaceuticals' top insider investors include:
  1. James Graham (Insider)
  2. Michele Dilizia (Insider)
Learn More about top insider investors at Recce Pharmaceuticals.